Do interventions that address patient cost-sharing improve adherence to prescription drugs? A systematic review of recently published studies

References

• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497.
   PubMed Web of Science ®Google Scholar
• Blanchard J, Madden JM, Ross-Degnan D, et al. The relationship between emergency department use and cost-related medication nonadherence among medicare beneficiaries. Ann Emerg Med. 2013;62(5):475–485.
   PubMed Web of Science ®Google Scholar
• Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007 Jul 4;298(1):61–69.
   PubMed Web of Science ®Google Scholar
• Heisler M, Langa KM, Eby EL, et al. The health effects of restricting prescription medication use because of cost. Med Care. 2004;42(7):626–634.
   PubMed Web of Science ®Google Scholar
• Soumerai SB, McLaughlin TJ, Ross-Degnan D, et al. Effects of a limit on medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia. N Engl J Med. 1994;331(10):650–655.
   PubMed Web of Science ®Google Scholar
• Kaiser Family Foundation. The medicare part D prescription drug benefit; 2018 [cited 2019 Jan 16]. Available from: http://kff.org/medicare/fact-sheet/the-medicare-prescription-drug-benefit-fact-sheet/
   Google Scholar
• Lee JL, Maciejewski ML, Raju SS, et al. Value-based insurance design: quality improvement but no cost savings. Health Aff (Millwood). 2013;32(7):1251–1257.
   PubMed Web of Science ®Google Scholar
• Look KA. Value-based insurance design and medication adherence: opportunities and challenges. Am J Manag Care. 2015 Jan 1;21(1):e78–e90.
   PubMed Web of Science ®Google Scholar
• Viswanathan M, Golin CE, Jones CD, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med. 2012 Dec 4;157(11):785–795.
   PubMed Web of Science ®Google Scholar
• Peaslee A, Wickizer M, Olson J, et al. Impact of a combined value-based insurance design and medication therapy management program on diabetes medication adherence. J Manag Care Spec Pharm. 2016;22(11):1303–1309.
   PubMed Web of Science ®Google Scholar
• Yeung K, Basu A, Hansen RN, et al. Impact of a value-based formulary on medication utilization, health services utilization, and expenditures. Med Care. 2017;55(2):191–198.
   PubMed Web of Science ®Google Scholar
• Hirth RA, Cliff EQ, Gibson TB, et al. Connecticut’s value-based insurance plan increased the use of targeted services and medication adherence. Health Aff (Millwood). 2016;35(4):637–646.
   PubMed Web of Science ®Google Scholar
• Maeng DD, Pitcavage JM, Snyder SR, et al. The value of value-based insurance design: savings from eliminating drug co-payments. Am J Manag Care. 2016;22(2):116–121.
   PubMed Web of Science ®Google Scholar
• Lewey J, Shrank WH, Avorn J, et al. Medication adherence and healthcare disparities: impact of statin co-payment reduction. Am J Manag Care. 2015;21(10):696–704.
   PubMed Web of Science ®Google Scholar
• Sullivan SD, Yeung K, Vogeler C, et al. Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm. 2015;21(4):269–275.
   PubMed Web of Science ®Google Scholar
• Musich S, Wang S, Hawkins K. The impact of a value-based insurance design plus health coaching on medication adherence and medical spending. Popul Health Manag. 2015;18(3):151–158.
   PubMed Web of Science ®Google Scholar
• Maciejewski ML, Wansink D, Lindquist JH, et al. Value-based insurance design program in north carolina increased medication adherence but was not cost neutral. Health Aff (Millwood). 2014;33(2):300–308.
   PubMed Web of Science ®Google Scholar
• Clark B, DuChane J, Hou J, et al. Evaluation of increased adherence and cost savings of an employer value-based benefits program targeting generic antihyperlipidemic and antidiabetic medications. J Manag Care Pharm. 2014;20(2):141–150.
   PubMed Web of Science ®Google Scholar
• Elliott DJ, Robinson EJ, Anthony KB, et al. Patient-centered outcomes of a value-based insurance design program for patients with diabetes. Popul Health Manag. 2013;16(2):99–106.
   PubMed Web of Science ®Google Scholar
• Frank MB, Fendrick AM, He Y, et al. The effect of a large regional health plan’s value-based insurance design program on statin use. Med Care. 2012;50(11):934–939.
   PubMed Web of Science ®Google Scholar
• Farley JF, Wansink D, Lindquist JH, et al. Medication adherence changes following value-based insurance design. Am J Manag Care. 2012;18(5):265–274.
   PubMed Web of Science ®Google Scholar
• Kogut SJ, Johnson S, Higgins T, et al. Evaluation of a program to improve diabetes care through intensified care management activities and diabetes medication copayment reduction. J Manag Care Pharm. 2012;18(4):297–310.
   PubMed Web of Science ®Google Scholar
• Kim YA, Loucks A, Yokoyama G, et al. Evaluation of value-based insurance design with a large retail employer. Am J Manag Care. 2011;17(10):682–690.
   PubMed Web of Science ®Google Scholar
• Choudhry NK, Avorn J, Glynn RJ, et al. Full coverage for preventive medications after myocardial infarction. N Engl J Med. 2011;365(22):2088–2097.
   PubMed Web of Science ®Google Scholar
• Gibson TB, Wang S, Kelly E, et al. A value-based insurance design program at a large company boosted medication adherence for employees with chronic illnesses. Health Aff (Millwood). 2011;30(1):109–117.
   PubMed Web of Science ®Google Scholar
• Maciejewski ML, Farley JF, Parker J, et al. Copayment reductions generate greater medication adherence in targeted patients. Health Aff (Millwood). 2010;29(11):2002–2008.
   PubMed Web of Science ®Google Scholar
• Nair KV, Miller K, Park J, et al. Prescription co-pay reduction program for diabetic employees. Popul Health Manag. 2010;13(5):235–245.
   PubMed Web of Science ®Google Scholar
• Mahoney JJ. Value-based benefit design: using a predictive modeling approach to improve compliance. J Manag Care Pharm. 2008;14(6 Suppl B):3–8.
   PubMed Web of Science ®Google Scholar
• Gibson TB, Mahoney J, Ranghell K, et al. Value-based insurance plus disease management increased medication use and produced savings. Health Aff (Millwood). 2011;30(1):100–108.
   PubMed Web of Science ®Google Scholar
• Zeng F, An JJ, Scully R, et al. The impact of value-based benefit design on adherence to diabetes medications: a propensity score-weighted difference in difference evaluation. Value Health. 2010;13(6):846–852.
   PubMed Web of Science ®Google Scholar
• Chernew ME, Shah MR, Wegh A, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood). 2008;27(1):103–112.
   PubMed Web of Science ®Google Scholar
• Choudhry NK, Fischer MA, Avorn J, et al. At Pitney Bowes, value-based insurance design cut copayments and increased drug adherence. Health Aff (Millwood). 2010;29(11):1995–2001.
   PubMed Web of Science ®Google Scholar
• Reed ME, Warton EM, Kim E, et al. Value-based insurance design benefit offsets reductions in medication adherence associated with switch to deductible plan. Health Aff (Millwood). 2017;36(3):516–523.
   PubMed Web of Science ®Google Scholar
• Choudhry NK, Fischer MA, Avorn JL, et al. The impact of reducing cardiovascular medication copayments on health spending and resource utilization. J Am Coll Cardiol. 2012;60(18):1817–1824.
   PubMed Web of Science ®Google Scholar
• Mahoney JJ. Reducing patient drug acquisition costs can lower diabetes health claims. Am J Manag Care. 2005;11(5 Suppl):S170–S176.
   PubMed Web of Science ®Google Scholar
• Rodin HA, Heaton AH, Wilson AR, et al. Plan designs that encourage the use of generic drugs over brand-name drugs: an analysis of a free generic benefit. Am J Manag Care. 2009;15(12):881–888.
   PubMed Web of Science ®Google Scholar
• Dunn JD, Cannon E, Mitchell MP, et al. Utilization and drug cost outcomes of a step-therapy edit for generic antidepressants in an HMO in an integrated health system. J Manag Care Pharm. 2006;12:294–302.
   PubMed Web of Science ®Google Scholar
• Dusetzina SB. Share of specialty drugs in commercial plans nearly quadrupled, 2003-14. Health Aff (Millwood). 2016;35(7):1241–1246.
   PubMed Web of Science ®Google Scholar
• Bradley CJ, Yabroff KR, Warren JL, et al. Trends in the treatment of metastatic colon and rectal cancer in elderly patients. Med Care. 2016;54(5):490–497.
   PubMed Web of Science ®Google Scholar
• Bradley CJ, Yabroff KR, Mariotto A, et al. Antineoplastic treatment of advanced non-small cell lung cancer: treatment, survival, and spending (2000–2011). J Clin Oncol. 2017;35(5):529–535.
   Google Scholar
• Ubel PA, Abernethy AP, Zafar SY. Full disclosure–out-of-pocket costs as side effects. N Engl J Med. 2013;369(16):1484–1486.
   PubMed Web of Science ®Google Scholar
• Peters JL, Sutton AJ, Jones DR, et al. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–680.
   PubMed Web of Science ®Google Scholar
• Conn VS, Ruppar TM, Enriquez M, et al. Patient-centered outcomes of medication adherence interventions: systematic review and meta-analysis. Value Health. 2016;19(2):277–285.
   PubMed Web of Science ®Google Scholar
• Boswell KA, Cook CL, Burch SP, et al. Associating medication adherence with improved outcomes: a systematic literature review. Am J Pharm Benefits. 2012;4(4):e97–e108.
   Google Scholar